News | January 27, 2012

Crux Biomedical's IVC Filter Receives CE Mark Approval

January 27, 2012 — Crux Biomedical announced it received CE mark approval for its inferior vena cava filter (IVCF) with bi-directional retrieval (BDR).  Vena cava filters are designed to trap blood clots that can lead to a potentially fatal pulmonary embolism (PE).  Each year in the United States, approximately 600,000 patients develop a PE and an estimated 200,000 deaths occur.

The Crux Biomedical IVCF was designed to address the limitations of currently available vena cava filters including perforation, migration and inability to retrieve. "Crux was able to design a device that is both more versatile and simple to use," said Tom Fogarty, M.D., cardiovascular surgeon and founder of Crux Biomedical. 

"We are extremely pleased with the results from the recently completed pivotal trial performed at 22 centers of excellence in the United States, Australia, New Zealand and Belgium. Our device demonstrated an excellent safety profile. The Crux device could be retrieved with a 98 percent success rate," stated Mel Schatz, CEO of Crux Biomedical. The company anticipates submission to the U.S. Food and Drug Administration (FDA) in January and approval in 2012.

For more information: www.cruxbiomedical.com

Related Content

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
News | January 21, 2015
The number of IVC filters placed has more than doubled in the last 10 years, and by some estimates, less than half of...
Vena Cava Filters, Embolic protection, Pulmonary Embolism, Venous Therapies

Image courtesy of Society of Vascular Surgery

Feature | January 05, 2015
The first large-scale, multispecialty prospective clinical research trial to evaluate the use of inferior vena cava (...
News | August 06, 2014
Decision Resources Group finds that the United States clot management device market will expand through 2022,...
Cook Medical SCAI CIVIC PRESERVE Clincal Studies Vena Cava Filter
News | June 05, 2014
Cook Medical is engaged in two clinical studies that will provide additional data on the safety and effectiveness of...
Argon Medical OptionElite retrievable inferior vena cava (IVC) filter guidewire
Technology | January 23, 2014
Argon Medical Devices Inc. received clearance from the U.S. Food and Drug Administration (FDA) to begin marketing the...
Angiotech Vena Cava Filter
News | April 18, 2013
One venous puncture, rather than two, is a safe and effective approach to intravascular ultrasound-guided inferior vena...
News | April 05, 2013
Continuing its commitment to provide best-in-class medical devices for the prevention of recurrent pulmonary embolism (...
Sponsored Content | Videos | Vena Cava Filters| July 24, 2012
This video, provided by Crux Biomedical, demonstrates the implantation of the FDA-cleared Crux VCF inferior vena cava
Technology | July 20, 2012
July 20, 2012 — Crux Biomedical announced it has received U.S. Food and Drug Administration (FDA) clearance for its...
Overlay Init